Nuveen Asset Management LLC Acquires 46,594 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Nuveen Asset Management LLC boosted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 519,019 shares of the medical device company's stock after buying an additional 46,594 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.79% of Tandem Diabetes Care worth $18,695,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its position in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after buying an additional 1,101 shares during the period. US Bancorp DE grew its position in Tandem Diabetes Care by 15.2% during the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after buying an additional 5,108 shares during the period. KBC Group NV grew its position in Tandem Diabetes Care by 41.5% during the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock valued at $6,933,000 after buying an additional 56,461 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in Tandem Diabetes Care by 22.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock valued at $236,000 after buying an additional 1,184 shares during the period. Finally, Vanguard Group Inc. grew its position in Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after buying an additional 77,451 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TNDM. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Robert W. Baird cut their target price on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. The Goldman Sachs Group cut their target price on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Canaccord Genuity Group increased their target price on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Finally, Wells Fargo & Company cut their target price on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.47.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.90% of the stock is currently owned by insiders.

Tandem Diabetes Care Price Performance

Shares of TNDM stock traded up $0.76 during trading hours on Tuesday, reaching $21.48. The stock had a trading volume of 1,448,510 shares, compared to its average volume of 1,487,141. The stock's fifty day simple moving average is $19.40 and its 200 day simple moving average is $27.35. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69. The firm has a market capitalization of $1.43 billion, a PE ratio of -11.13 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.65) earnings per share. On average, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.